We are live on ! Find out more
MIST icon

Milestone Pharmaceuticals
MIST

29 hedge funds and large institutions have $116M invested in Milestone Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

547% more call options, than puts

Call options by funds: $1.77M | Put options by funds: $273K

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

4% more funds holding

Funds holding: 28 → 29 (+1)

0.77% less ownership

Funds ownership: 70.35% → 69.58% (-0.77%)

14% less capital invested

Capital invested by funds: $135M → $116M (-$19.1M)

25% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 8

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
29
Holders Change
+1
Holders Change %
+3.57%
% of All Funds
0.49%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
4
Increased
6
Reduced
8
Closed
2
Calls
$1.77M
Puts
$273K
Net Calls
+$1.49M
Net Calls Change
+$325K

Top Buyers

1
Morgan Stanley
Morgan Stanley
New York
+$3.07M
2
LPC
Lion Point Capital
New York
+$1.63M
3
BL
Bleichroeder LP
New York
+$1.61M
4
ACP
Acuta Capital Partners
California
+$474K
5
Millennium Management
Millennium Management
New York
+$427K

Top Sellers

1
O
OrbiMed
New York
-$4.71M
2
IC
Ikarian Capital
Texas
-$3.38M
3
BFM
Boothbay Fund Management
New York
-$318K
4
Barclays
Barclays
United Kingdom
-$92.2K
5
PP
PDT Partners
New York
-$65K
Name Holding Trade Value Shares
Change 		Change in
Stake
RI
1
RTW Investments
New York
$26.5M – – –
NHAS
2
Novo Holdings A/S
Denmark
$15.6M – – –
RCM
3
RA Capital Management
Massachusetts
$13.8M – – –
BC
4
Boxer Capital
California
$13.8M – – –
IC
5
Ikarian Capital
Texas
$8.19M -$3.38M -549,330 -28%
Morgan Stanley
6
Morgan Stanley
New York
$8.11M +$3.07M +499,533 +61%
Millennium Management
7
Millennium Management
New York
$8.07M +$427K +69,439 +5%
PVI
8
Pura Vida Investments
New York
$6.07M – – –
LPC
9
Lion Point Capital
New York
$5.63M +$1.63M +265,000 +39%
BL
10
Bleichroeder LP
New York
$3.04M +$1.61M +262,500 +105%
ACP
11
Acuta Capital Partners
California
$2.81M +$474K +77,200 +20%
Barclays
12
Barclays
United Kingdom
$1.3M -$92.2K -15,000 -7%
EP
13
Eversept Partners
New York
$905K – – –
BFM
14
Boothbay Fund Management
New York
$815K -$318K -51,697 -28%
Dimensional Fund Advisors
15
Dimensional Fund Advisors
Texas
$448K +$83.6K +13,603 +22%
State Street
16
State Street
Massachusetts
$128K -$1.19K -194 -0.9%
Royal Bank of Canada
17
Royal Bank of Canada
Ontario, Canada
$114K -$49.2K -8,002 -30%
Susquehanna International Group
18
Susquehanna International Group
Pennsylvania
$108K +$112K +18,233 New
Geode Capital Management
19
Geode Capital Management
Massachusetts
$104K – – –
National Bank of Canada
20
National Bank of Canada
Quebec, Canada
$88K – – –
Acadian Asset Management
21
Acadian Asset Management
Massachusetts
$84K -$34.1K -5,553 -29%
Goldman Sachs
22
Goldman Sachs
New York
$74K – – –
LP
23
LMR Partners
United Kingdom
$72K +$72.1K +11,732 New
FDCDDQ
24
Federation des caisses Desjardins du Quebec
Quebec, Canada
$64.6K – – –
JP Morgan Chase
25
JP Morgan Chase
New York
$21K -$61.7K -10,041 -74%
1
2

MIST Hedge Fund Activity: Q2 2022 in Review

29 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Milestone Pharmaceuticals (MIST) for Q2 2022, worth a combined $116M — down 14% from $135M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new MIST positions and 2 closed out — a net gain of 2 holders — while 6 added to existing stakes and 8 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $3.07M. The largest seller was OrbiMed, cutting an estimated $4.71M.

  • 29 institutional investors held Milestone Pharmaceuticals (MIST) as of Q2 2022, up from 28 in Q1 2022.
  • Funds reported $116M of Milestone Pharmaceuticals stock for Q2 2022, down 14% quarter-over-quarter.
  • 4 funds opened new Milestone Pharmaceuticals positions in Q2 2022 and 2 closed out, a net change of +2 holders.
  • The largest Milestone Pharmaceuticals buyer in Q2 2022 was Morgan Stanley, an estimated $3.07M added.
  • The largest Milestone Pharmaceuticals seller in Q2 2022 was OrbiMed, an estimated $4.71M sold.

Based on aggregated 13F filings for Q2 2022.